Acquisition History / Charles River Laboratories International, Inc. / PathoQuest SAS
Charles River Laboratories International, Inc. Acquires PathoQuest SAS
Announced January 12, 2026 — $60.4M
What happened
Charles River agreed to acquire the remaining ~79% equity stake in Paris-based PathoQuest, a next-generation-sequencing biosafety and viral-safety testing provider, for EUR 51.6 million, taking it to 100% ownership (Charles River had held ~21% since 2018).
- Target
- PathoQuest SAS
- Announced
- January 12, 2026
- Price
- $60.4M
- Industry
- Biopharma quality-control testing (NGS-based biosafety testing)
- Buyer type
- Strategic acquirer
- Status
- Closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Charles River Laboratories International, Inc. acquire PathoQuest SAS?
Charles River Laboratories International, Inc. acquired PathoQuest SAS on January 12, 2026. This was Charles River Laboratories International, Inc.'s 1st publicly tracked acquisition out of 1 we have on record.
How much did Charles River Laboratories International, Inc. pay for PathoQuest SAS?
Charles River Laboratories International, Inc. paid $60.4M for PathoQuest SAS.
What does PathoQuest SAS do?
Charles River agreed to acquire the remaining ~79% equity stake in Paris-based PathoQuest, a next-generation-sequencing biosafety and viral-safety testing provider, for EUR 51.6 million, taking it to 100% ownership (Charles River had held ~21% since 2018).
What other Biopharma quality-control testing (NGS-based biosafety testing) companies has Charles River Laboratories International, Inc. acquired?
PathoQuest SAS is Charles River Laboratories International, Inc.'s only publicly tracked acquisition in Biopharma quality-control testing (NGS-based biosafety testing) so far.